Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25345519 | 0.70 | NR1H2 (0.50) | — | |
| SCHEMBL24800426 | 0.68 | ADORA3 (0.36) | ADORA3ADORA1 | |
| SCHEMBL25346316 | 0.67 | MEN1 (0.32) | DAO | |
| SCHEMBL25609010 | 0.66 | KDM4E (0.33) | DAO | |
| SCHEMBL23755908 | 0.66 | ADORA3 (0.37) | ADORA3ADORA1 | |
| SCHEMBL18638124 | 0.64 | ADORA3 (0.39) | ADORA3ADORA1 | |
| SCHEMBL25094304 | 0.63 | ADORA3 (0.33) | ADORA3ADORA1 | |
| SCHEMBL25094712 | 0.63 | ADORA3 (0.33) | ADORA3ADORA1 | |
| SCHEMBL18704099 | 0.59 | PARP1 (0.33) | — | |
| SCHEMBL25080155 | 0.59 | TNKS (0.38) | ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORP (US) | 2025-09-11 | — | — | US | disclosed |
| CN-119212994-A | Pyrazolopyrazine compounds as SHP2 inhibitors | 建新公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4448526-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4227307-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | Genzyme Corporation (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023114954-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | PTPN5, PTPN2, PTPRJ | ADORA3 4820/4885DAO 4538/4885ADORA1 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.